NasdaqGS - Nasdaq Real Time Price USD

Treace Medical Concepts, Inc. (TMCI)

5.04 -0.59 (-10.48%)
As of 2:24 PM EDT. Market Open.
Loading Chart for TMCI
DELL
  • Previous Close 5.63
  • Open 5.75
  • Bid 5.03 x 100
  • Ask 5.07 x 2400
  • Day's Range 5.03 - 5.75
  • 52 Week Range 3.92 - 27.70
  • Volume 1,154,245
  • Avg. Volume 946,775
  • Market Cap (intraday) 312.521M
  • Beta (5Y Monthly) 0.37
  • PE Ratio (TTM) --
  • EPS (TTM) -0.88
  • Earnings Date Aug 6, 2024 - Aug 12, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 6.60

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

www.treace.com

516

Full Time Employees

December 31

Fiscal Year Ends

Recent News: TMCI

Performance Overview: TMCI

Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TMCI
60.47%
S&P 500
10.83%

1-Year Return

TMCI
80.36%
S&P 500
28.63%

3-Year Return

TMCI
82.88%
S&P 500
26.66%

5-Year Return

TMCI
79.43%
S&P 500
26.47%

Compare To: TMCI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TMCI

Valuation Measures

Annual
As of 5/16/2024
  • Market Cap

    349.11M

  • Enterprise Value

    309.21M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.77

  • Price/Book (mrq)

    2.76

  • Enterprise Value/Revenue

    1.58

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -27.93%

  • Return on Assets (ttm)

    -14.33%

  • Return on Equity (ttm)

    -38.55%

  • Revenue (ttm)

    196.03M

  • Net Income Avi to Common (ttm)

    -54.75M

  • Diluted EPS (ttm)

    -0.88

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    110.01M

  • Total Debt/Equity (mrq)

    55.47%

  • Levered Free Cash Flow (ttm)

    -25.39M

Research Analysis: TMCI

Company Insights: TMCI

Research Reports: TMCI

People Also Watch